Wegovy max dose: what it is, and what reaching it actually means

The myth: the highest dose is always the goal you should push for

A lot of people arrive at this question with the reasonable assumption that more equals better, that if 2.4 mg produces good results, then 7.2 mg must produce dramatically greater ones, and anything less is leaving something on the table. That framing gets the dose-escalation process slightly wrong.

The dose schedule for Wegovy exists the way it does because semaglutide's gastrointestinal effects (nausea is the most common) are dose-dependent. Starting low and moving slowly gives your system time to settle. The first several months of treatment are as much about finding the dose your body tolerates well as they are about weight loss itself. A prescriber may keep you at an intermediate dose for longer if you're responding well or finding a particular step uncomfortable, and that's good clinical practice, not a shortcut.

If you want to understand what the maximum dose of semaglutide means across the full treatment pathway, it helps to know that "maximum" in this context means the ceiling the MHRA has assessed as safe under medical supervision, not a target every patient is expected to reach. If you're losing weight meaningfully at 1.7 mg with minimal side effects, there may be little clinical reason to increase further. That's a conversation for you and your prescriber, not a decision to make based on what you've read online.

For a fuller picture of how the full dose range sits in the treatment pathway, the Wegovy doses guide on this site covers each step in detail.

What the MHRA actually approved, and when

The 7.2 mg maximum dose has a recent history worth knowing. Semaglutide 2.4 mg was Wegovy's standard maintenance dose at launch. In January 2026, the MHRA approved 7.2 mg as a higher maintenance option, initially delivered as three 2.4 mg pens taken in a single weekly session. Then, on 14 April 2026, the MHRA approved a dedicated Wegovy 7.2 mg single-dose pen, one auto-injecting pen per week, with a built-in covered needle that locks after use. The UK was ahead of most of Europe in both approvals.

That dedicated pen matters practically. For patients who have already titrated up through the standard steps and reached 2.4 mg as their maintenance dose, moving to 7.2 mg doesn't mean starting over. The titration schedule (0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, then potentially to 7.2 mg) still applies if you're starting fresh, with roughly four weeks at each level before any increase.

It's worth noting the 7.2 mg approval is specifically for adults with a BMI of 30 or above, it doesn't extend the licence to people with a lower BMI who hold a weight-related health condition, as the 2.4 mg licence does. The maximum Wegovy dose for weight loss page goes into the licensing detail if you want the full breakdown.

As with all Wegovy doses, this is a Black Triangle medicine, meaning the MHRA requires additional monitoring as post-market safety data continues to accumulate. People sometimes ask whether Wegovy increases the risk of cancer, and that page addresses what the current evidence and ongoing monitoring actually show. You can also report any suspected side effects via the MHRA's Yellow Card scheme.

What the trial results at 7.2 mg actually showed

The clinical data for the higher dose is genuinely promising. Trials reported an average body-weight reduction of around 20.7% over 72 weeks at 7.2 mg, closing the gap considerably with tirzepatide's results in the SURMOUNT programme. For context, the STEP 1 trial, published in the New England Journal of Medicine, showed around 15% average reduction at 2.4 mg over 68 weeks. The step up to 7.2 mg represents a meaningful clinical difference, not just a marginal one.

If you're curious how the max dose compares to Wegovy's standard results, the maximum weight loss on Wegovy page explores that in more depth.

What trial averages don't tell you is where you'll land individually. Weight-loss response varies considerably between people, influenced by baseline weight, how long you've been on treatment, your diet and activity, and your biology. Some people see the steepest losses at intermediate doses; others respond particularly well at the ceiling. There's no reliable way to predict which category you'll fall into before treatment starts, which is part of why clinical review at each step matters. Wegovy is a prescription-only medicine; a prescriber, not a fixed algorithm, makes the call on whether to increase.

The NHS semaglutide medicines page has a plain-English summary of how the medicine works and what to expect, including a side-effects overview.

What reaching the maximum dose looks like in practice

If you're on a private treatment pathway and your prescriber decides 7.2 mg is appropriate, you'll have been on treatment for roughly five months or more by the time you reach it, assuming a standard four-weekly titration and no pauses for tolerability. That's not a criticism of the process; it's the design working as intended.

Side effects at 7.2 mg are broadly similar in type to lower doses (nausea, loose stools, constipation, reflux) but may be more pronounced, particularly in the weeks immediately after an increase. Most people find these settle. If they don't, staying at 2.4 mg or an intermediate dose is a legitimate clinical option, not a failure.

If you're weighing up the cost of ongoing treatment at a higher dose, the Wegovy price comparison UK page covers what the private market currently looks like and what a legitimate prescription price includes.

At nume, every dose increase is reviewed clinically before it's approved, a named prescriber looks at your records, not a queue for a piece of software. If you'd like to explore whether Wegovy could be right for you, or discuss where you are in an existing treatment journey, you're welcome to start a free consultation with our team.